Gachon University has divulged quinoxaline compounds acting as proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutant inhibitors reported to be useful for the treatment of cancer.
Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals Inc. potentially worth $117.5 million, now that Roche Holding AG has relinquished all rights. The product, a once-daily oral small-molecule kinase inhibitor of wild-type RET (rearranged during transfection) and oncogenic RET fusions, received accelerated approval in 2020 by the U.S. FDA, under priority review and with orphan drug designation, to treat adults with metastatic RET fusion-positive non-small-cell lung cancer.
A Pelemed Co. Ltd. patent details new indirubin derivatives acting as inhibitors of FLT3 (FLK2/STK1) and/or proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutants. They are reported to be useful for the treatment of acute myeloid leukemia.
Researchers from TYK Medicines Inc. have reported the discovery and preclinical evaluation of TY-1091, a second-generation RET inhibitor being developed for the treatment of RET-mutant cancers.
Stemline Therapeutics Inc. has identified proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) (mutant) inhibitors reported to be useful for the treatment of cancer.
Diwali, the Festival of Light, marks different events depending on where it is celebrated. In some areas of India, it marks the return of Lord Rama to his birthplace of Ayodhya after defeating the demon Ravana.
Diwali, the Festival of Light, marks different events depending on where it is celebrated. In some areas of India, it marks the return of Lord Rama to his birthplace of Ayodhya after defeating the demon Ravana. For Vivek Subbiah, associate professor at the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine of the MD Anderson Cancer Center, the story of how Rama defeated Ravana has parallels in drug discovery. Ravana had 10 heads, and when one was cut off, it grew back. Rama defeated Ravana by means of a magic arrow that entered through the demon’s navel.
Proto-oncogene tyrosine-protein kinase receptor Ret is a widely expressed oncogene and chromosomal rearrangements involving RET lead to fusion genes and RET kinase activation, which occur in lung cancer in about in 2% of cases of non-small cell lung cancer.
